Tissue & cell · 2025
A combined therapeutic approach: Parthenolide and vincristine modulate autophagy in B-cell acute lymphoblastic leukemia.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zarei Elmira, Namdari Sepide, Zare Farahnaz, Dehbidi Gholamreza Rafiei, Nazari Mansoureh, Tamaddon Gholamhossein, Omidkhoda Azadeh
Аннотация
BACKGROUND: Parthenolide (PTL), derived from Tanacetum parthenium, is known for its anti-inflammatory and anti-cancer properties, primarily through NF-κB inhibition and modulation of reactive oxygen species. This study investigates PTL's potential as a complementary treatment for B-Cell Acute Lymphoblastic Leukemia, focusing on its effects on autophagy, apoptosis, and proliferation in the Nalm-6 cell line, alongside vincristine, with the aim of addressing challenges such as multi-drug resistance.
METHODS: Nalm-6 cells were treated with increasing concentrations of PTL and VCR to determine their IC50 values, followed by combination treatments with sub-IC50 doses. Apoptosis was assessed using flow cytometry, while changes in autophagy-related gene expression (BECN1, ATG10, LC3, and P62) were measured via Real-time PCR, and LC3 protein levels were analyzed through Immunoblotting.
RESULTS: The results revealed that both PTL and VCR inhibited Nalm-6 cell proliferation in a concentration and time-dependent manner, with a synergistic effect observed in combined treatments. This combination also increased apoptosis and significantly enhanced the expression of autophagy-related genes ATG10, LC3 and BECN1 while decreasing P62 expression. Additionally, VCR and PTL increased LC3B-II protein levels.
CONCLUSION: Overall, the study indicates that combined treatment promotes autophagy and apoptosis, suggesting that PTL could be a beneficial adjunct to chemotherapy for treating B-ALL in the future.
METHODS: Nalm-6 cells were treated with increasing concentrations of PTL and VCR to determine their IC50 values, followed by combination treatments with sub-IC50 doses. Apoptosis was assessed using flow cytometry, while changes in autophagy-related gene expression (BECN1, ATG10, LC3, and P62) were measured via Real-time PCR, and LC3 protein levels were analyzed through Immunoblotting.
RESULTS: The results revealed that both PTL and VCR inhibited Nalm-6 cell proliferation in a concentration and time-dependent manner, with a synergistic effect observed in combined treatments. This combination also increased apoptosis and significantly enhanced the expression of autophagy-related genes ATG10, LC3 and BECN1 while decreasing P62 expression. Additionally, VCR and PTL increased LC3B-II protein levels.
CONCLUSION: Overall, the study indicates that combined treatment promotes autophagy and apoptosis, suggesting that PTL could be a beneficial adjunct to chemotherapy for treating B-ALL in the future.